Quote:

---

so ohm, what say you?

---

Looking at the patent that expires in 2031 we're covered. Anyone basing leronlimab on the original patent would be stuck with a very low dose ineffective version of leronlimab. What kind of receptor occupancy and efficacy would you get at 175mg or less?

https://patents.justia.com/patent/9956165

Cytodyn's patents if anyone's interested -

https://patents.google.com/?assignee=Cytodyn+Inc